283 related articles for article (PubMed ID: 35209934)
1. Effect of fecal microbiota transplantation on primary hypertension and the underlying mechanism of gut microbiome restoration: protocol of a randomized, blinded, placebo-controlled study.
Fan L; Ren J; Chen Y; Wang Y; Guo Z; Bu P; Yang J; Ma W; Zhu B; Zhao Y; Cai J
Trials; 2022 Feb; 23(1):178. PubMed ID: 35209934
[TBL] [Abstract][Full Text] [Related]
2. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
3. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
[TBL] [Abstract][Full Text] [Related]
4. Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial.
Yu EW; Gao L; Stastka P; Cheney MC; Mahabamunuge J; Torres Soto M; Ford CB; Bryant JA; Henn MR; Hohmann EL
PLoS Med; 2020 Mar; 17(3):e1003051. PubMed ID: 32150549
[TBL] [Abstract][Full Text] [Related]
5. Effects of Fecal Microbiome Transfer in Adolescents With Obesity: The Gut Bugs Randomized Controlled Trial.
Leong KSW; Jayasinghe TN; Wilson BC; Derraik JGB; Albert BB; Chiavaroli V; Svirskis DM; Beck KL; Conlon CA; Jiang Y; Schierding W; Vatanen T; Holland DJ; O'Sullivan JM; Cutfield WS
JAMA Netw Open; 2020 Dec; 3(12):e2030415. PubMed ID: 33346848
[TBL] [Abstract][Full Text] [Related]
6. Effect of a probiotic on blood pressure in grade 1 hypertension (HYPRO): protocol of a randomized controlled study.
Mähler A; Wilck N; Rauch G; Dechend R; Müller DN
Trials; 2020 Dec; 21(1):1032. PubMed ID: 33375942
[TBL] [Abstract][Full Text] [Related]
7. Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study.
Jitsumura M; Cunningham AL; Hitchings MD; Islam S; Davies AP; Row PE; Riddell AD; Kinross J; Wilkinson TS; Jenkins GJ; Williams JG; Harris DA
BMJ Open; 2018 Oct; 8(10):e021987. PubMed ID: 30341117
[TBL] [Abstract][Full Text] [Related]
8. Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients.
Allegretti JR; Kassam Z; Mullish BH; Chiang A; Carrellas M; Hurtado J; Marchesi JR; McDonald JAK; Pechlivanis A; Barker GF; Miguéns Blanco J; Garcia-Perez I; Wong WF; Gerardin Y; Silverstein M; Kennedy K; Thompson C
Clin Gastroenterol Hepatol; 2020 Apr; 18(4):855-863.e2. PubMed ID: 31301451
[TBL] [Abstract][Full Text] [Related]
9. Protocol for the Gut Bugs Trial: a randomised double-blind placebo-controlled trial of gut microbiome transfer for the treatment of obesity in adolescents.
Leong KSW; Jayasinghe TN; Derraik JGB; Albert BB; Chiavaroli V; Svirskis DM; Beck KL; Conlon CA; Jiang Y; Schierding W; Vatanen T; Holland DJ; O'Sullivan JM; Cutfield WS
BMJ Open; 2019 Apr; 9(4):e026174. PubMed ID: 31005929
[TBL] [Abstract][Full Text] [Related]
10. Transfer of FRozen Encapsulated multi-donor Stool filtrate for active ulcerative Colitis (FRESCO): study protocol for a prospective, multicenter, double-blind, randomized, controlled trial.
Stallmach A; Grunert P; Stallhofer J; Löffler B; Baier M; Rödel J; Kiehntopf M; Neugebauer S; Pieper DH; Junca H; Tannapfel A; Merkel U; Schumacher U; Breternitz-Gruhne M; Heller T; Schauer A; Hartmann M; Steube A
Trials; 2022 Feb; 23(1):173. PubMed ID: 35193638
[TBL] [Abstract][Full Text] [Related]
11. Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential.
Bulow C; Langdon A; Hink T; Wallace M; Reske KA; Patel S; Sun X; Seiler S; Jones S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2018 Nov; 3(6):. PubMed ID: 30463925
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
13. PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial.
Woodhouse CA; Patel VC; Goldenberg S; Sanchez-Fueyo A; China L; O'Brien A; Flach C; Douiri A; Shawcross D
BMJ Open; 2019 Feb; 9(2):e023518. PubMed ID: 30772848
[TBL] [Abstract][Full Text] [Related]
14. Strain engraftment competition and functional augmentation in a multi-donor fecal microbiota transplantation trial for obesity.
Wilson BC; Vatanen T; Jayasinghe TN; Leong KSW; Derraik JGB; Albert BB; Chiavaroli V; Svirskis DM; Beck KL; Conlon CA; Jiang Y; Schierding W; Holland DJ; Cutfield WS; O'Sullivan JM
Microbiome; 2021 May; 9(1):107. PubMed ID: 33985595
[TBL] [Abstract][Full Text] [Related]
15. Effects of Diet-Modulated Autologous Fecal Microbiota Transplantation on Weight Regain.
Rinott E; Youngster I; Yaskolka Meir A; Tsaban G; Zelicha H; Kaplan A; Knights D; Tuohy K; Fava F; Scholz MU; Ziv O; Rubin E; Tirosh A; Rudich A; Blüher M; Stumvoll M; Ceglarek U; Clement K; Koren O; Wang DD; Hu FB; Stampfer MJ; Shai I
Gastroenterology; 2021 Jan; 160(1):158-173.e10. PubMed ID: 32860791
[TBL] [Abstract][Full Text] [Related]
16. Fecal Microbiota Transplantation in Neurological Disorders.
Vendrik KEW; Ooijevaar RE; de Jong PRC; Laman JD; van Oosten BW; van Hilten JJ; Ducarmon QR; Keller JJ; Kuijper EJ; Contarino MF
Front Cell Infect Microbiol; 2020; 10():98. PubMed ID: 32266160
[No Abstract] [Full Text] [Related]
17. FTACMT study protocol: a multicentre, double-blind, randomised, placebo-controlled trial of faecal microbiota transplantation for autism spectrum disorder.
Chen Y; Xueying Z; Jiaqu C; Qiyi C; Huanlong Q; Ning L; Yasong D; Xiaoxin Z; Rong Y; Jubao L; Xiaoqiong L; Chunlian M; Yu W; Shidong C; Guifang K; Dongmei Z; Shuanfeng F; Xujing Z; Binrang Y; Yanxia W; Ling L; Song Y; Xiang Z; Beihua Z; Lin J; Hong J;
BMJ Open; 2022 Jan; 12(1):e051613. PubMed ID: 35105621
[TBL] [Abstract][Full Text] [Related]
18. Microbial Interventions to Control and Reduce Blood Pressure in Australia (MICRoBIA): rationale and design of a double-blinded randomised cross-over placebo controlled trial.
Rhys-Jones D; Climie RE; Gill PA; Jama HA; Head GA; Gibson PR; Kaye DM; Muir JG; Marques FZ
Trials; 2021 Jul; 22(1):496. PubMed ID: 34315522
[TBL] [Abstract][Full Text] [Related]
19. Fecal microbiota transplantation improves metabolic syndrome parameters: systematic review with meta-analysis based on randomized clinical trials.
Proença IM; Allegretti JR; Bernardo WM; de Moura DTH; Ponte Neto AM; Matsubayashi CO; Flor MM; Kotinda APST; de Moura EGH
Nutr Res; 2020 Nov; 83():1-14. PubMed ID: 32987284
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiota dysbiosis contributes to the development of hypertension.
Li J; Zhao F; Wang Y; Chen J; Tao J; Tian G; Wu S; Liu W; Cui Q; Geng B; Zhang W; Weldon R; Auguste K; Yang L; Liu X; Chen L; Yang X; Zhu B; Cai J
Microbiome; 2017 Feb; 5(1):14. PubMed ID: 28143587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]